Catalent Adopts Optofluidic Platform for Cell-Line Development
Catalent Pharma Solutions plans to adopt an optofluidic platform for cell-line development provided by Berkeley Lights (BLI), an Emeryville, California-headquartered company developing platforms for biopharmaceutical processes.
BLI’s Beacon optofluidic platform is capable of screening thousands of clones in parallel and can identify the top-producing clones in five days, according to information from Catalent. The four integrated workflows of the Beacon platform – import, culture, assay, and export, will be applied to Catalent Biologics’ GPEx cell-line development platform as well as Catalent’s ongoing research and development activities.
Source: Catalent Pharma Solutions